Skip to main content

FDA Approvals

FDA Approvals, Payers' Guide

FDA Approvals of Brand-Name Prescription Drugs in 2017

Payers' Guide, FDA Approvals

Xermelo (Telotristat Ethyl), First-in-Class Tryptophan Hydroxylase Inhibitor, Approved for Carcinoid Syndrome Diarrhea

Payers' Guide, FDA Approvals

Vyxeos (Daunorubicin and Cytarabine) Liposomal Combination First Treatment Approved for Patients with High-Risk Acute Myeloid Leukemia

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Tremfya (Guselkumab), First-in-Class IL-23 Blocker, Approved for the Treatment of Patients with Moderate-to-Severe Plaque Psoriasis

Payers' Guide, FDA Approvals

Simponi Aria (Golimumab), the Only Fully Human Anti–TNF-α Infused Therapy, Now Approved for Active Psoriatic Arthritis and for Active Ankylosing Spondylitis

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Siliq (Brodalumab) a New IL-17RA Antagonist Approved for Moderate-to-Severe Plaque Psoriasis

Payers' Guide, FDA Approvals

Shingrix (Zoster Vaccine Recombinant) a New Vaccine Approved for Herpes Zoster Prevention in Older Adults

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Nerlynx (Neratinib) First Extended Adjuvant Therapy Approved for HER2-Positive Breast Cancer

Payers' Guide, FDA Approvals

Kisqali (Ribociclib): Second CDK4/CDK6 Inhibitor Approved for Postmenopausal Women with HR-Positive, HER2-Negative Advanced Breast Cancer

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Imfinzi (Durvalumab) a New PD-L1 Inhibitor Approved for the Treatment of Advanced or Metastatic Urothelial Cancer

Lisa A. Raedler, PhD, RPh

Page 27 of 53
Results 261 - 270 of 522